All In Biotech

Drug Trial Radar · NCT03015311

Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients

Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial

Last checked: Nov 19, 2026Latest source record: Jul 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

8,000

Planned (sponsor's estimate)

Start

Jan 15, 2017

Primary completion

Dec 31, 2020

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The purpose of this trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal (\<130 mmHg, intensive treatment) than currently recommended (\<150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of old. Furthermore, this trial will also examine the effect of blood pressure APP management strategy via WeChat network on medication compliance, blood pressure control and CVD benefits.

Conditions

  • Primary Hypertension

Interventions

  • Intensive BP controlDrug

    For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.

  • Standard BP controlDrug

    For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary composite outcomeTime frame: 4 years

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital affiliated to Capical Medical University

    Beijing, Beijing Municipality, China

  • Bei Jing Hospital

    Beijing, Beijing Municipality, China

  • Chinese Academy of Medical Sciences, FuWai Hospital

    Beijing, Beijing Municipality, China

  • Xuanwu hospital of capital medical university

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Beijing Pinggu Hospital

    Beijing, Beijing Municipality, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Guangdong Cardiovascular Institute

    Guangzhou, Guangdong, China

  • Huizhou Municipal Central Hospital

    Huizhou, Guangdong, China

  • The Second Affiliated Hospital to Medical College Shantou University Guangdong

    Shantou, Guangdong, China

  • Shenzhen Sun Yat-sen Cardiovascular Hospital

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Guangxi University of Chinese Medicine

    Nanning, Guangxi, China

  • Kailua General Hospital

    Tangshan, Hebei, China

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei, China

  • First affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Hong xinglong center hospital

    Shuangyashan, Heilongjiang, China

  • First Affiliated Hospitalof Zhengzhou University

    Zhengzhou, Henan, China

  • Zhoukou City Central Hospital

    Zhoukou, Henan, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Kang Ya Hospita

    Yiyang, Hunan, China

  • The Second Affiliated Hospital of Baotou Medical College

    Baotou, Inner Mongolia, China

  • Zhenjiang First People's Hospital

    Zhenjiang, Jiangsu, China

  • the Second Affiliated Hospitalof NanChang University

    Nanchang, Jiangxi, China

  • Benxi Railway Hospital

    Benxi, Liaoning, China

  • The 1st Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The First People's Hospital of Yinchuan

    Yinchuan, Ningxia, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Shanghai general hospital, Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Shanxi caidiovascular hospital

    Taiyuan, Shanxi, China

  • Shanxi Academy of Medical Sciences, Shanxi Dayi Hospital

    Taiyuan, Shanxi, China

  • First Affiliated Hospital, Xian Jiaotong University

    Xi’an, Shanxi, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • College of Medicine , National Taiwan University

    Taibei, Taiwan, China

  • Pingjin Hospital, Logistics University of PAPF

    Tianjin, Tianjin Municipality, China

  • the People's Hospital of Ji Xian Distric

    Tianjin, Tianjin Municipality, China

  • First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • Yan'an Hospital affiliated to kunming medical university, Yunnan Cardiovascular Hospital

    Kunming, Yunnan, China

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.